直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 118849
タイトル別表記
AMD-associated submacular hemorrhage
著者
Inoue, Naomi Nagoya City University|J-CREST (Japanese Clinical Retina Study) Group
Kato, Aki Nagoya City University|J-CREST (Japanese Clinical Retina Study) Group
Araki, Takashi J-CREST (Japanese Clinical Retina Study) Group|Hyogo College of Medicine
Kimura, Takeshi J-CREST (Japanese Clinical Retina Study) Group|Hyogo College of Medicine
木下, 貴正 J-CREST (Japanese Clinical Retina Study) Group)|Sapporo City General Hospital
Okamoto, Fumiki J-CREST (Japanese Clinical Retina Study) Group|University of Tsukuba
Murakami, Tomoya J-CREST (Japanese Clinical Retina Study) Group|University of Tsukuba
三田村, 佳典 J-CREST (Japanese Clinical Retina Study) Group|Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
Sakamoto, Taiji J-CREST (Japanese Clinical Retina Study) Group|Kagoshima University
Miki, Akiko J-CREST (Japanese Clinical Retina Study) Group|Kobe University
Takamura, Yoshihiro J-CREST (Japanese Clinical Retina Study) Group|University of Fukui
Matsubara, Hisashi J-CREST (Japanese Clinical Retina Study) Group|Mie University
Tsujinaka, Hiroki J-CREST (Japanese Clinical Retina Study) Group|Nara Medical University
Gomi, Fumi J-CREST (Japanese Clinical Retina Study) Group|Hyogo College of Medicine
Yasukawa, Tsutomu Nagoya City University|J-CREST (Japanese Clinical Retina Study) Group
資料タイプ
学術雑誌論文
抄録
Purpose
To investigate the clinical features, treatment options, and visual outcomes of submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD).
Design
A retrospective, observational case series.
Methods
Setting: Multicenter institutional setting. Patient Population: A total of 127 patients (127 eyes; 88 men, 39 women; (mean age, 74.2 years)) diagnosed with AMD-associated SMHs exceeding 2 disc diameters involving the fovea. Observation: The AMD types, previous treatments, treatment options, anatomic findings, and best-corrected visual acuity (BCVA) were assessed. Main Outcome Measures: Clinical features, treatment options, and visual outcomes of SMHs secondary to nAMD.
Results
Thirty-two eyes had typical AMD, 94 eyes polypoidal choroidal vasculopathy (PCV), and one eye retinal angiomatous proliferation. Eighty-five eyes were treatment-naïve; 42 eyes were treated previously: anti-vascular endothelial growth factor (VEGF) therapy (n = 26), photodynamic therapy (n = 3), and combined therapy (n = 13). Treatment of SMHs included vitrectomy (36 eyes), pneumatic displacement (49 eyes), and anti-VEGF monotherapy (42 eyes). The final BCVA improved significantly in treatment-naïve cases from 0.86 to 0.62 logarithm of the minimal angle of resolution (logMAR) unit (Snellen equivalent from 20/145 to 20/83) and from 0.80 to 0.56 (Snellen equivalent from 20/126 to 20/73) in PCV cases. Meanwhile, the BCVA logMAR values improved from 1.15 to 0.75 (Snellen equivalent from 20/283 to 20/112) and from 0.87 to 0.63 (Snellen equivalent from 20/148 to 20/85) in eyes that underwent vitrectomy or pneumatic displacement, respectively. In eyes with BCVAs between 20/133 to 20/40 at SMH onset, the final VA in the pneumatic displacement group was better than in the anti-VEGF monotherapy group. One eye had a retinal detachment and 1 eye had a macular hole in the vitrectomy group, and 5 eyes had a vitreous hemorrhage in the pneumatic displacement group.
Conclusions
The recommended treatment for SMHs secondary to nAMD exceeding 2 disc area and with BCVA below 20/40 is vitrectomy or pneumatic displacement for visual improvement.
掲載誌名
PLOS ONE
ISSN
19326203
出版者
PLOS
17
7
開始ページ
e0271447
発行日
2022-07-21
権利情報
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
病院
医学系